Bioniche and Trophogen in license pact

Bioniche Life Sciences (TSX: BNC) has signed an exclusive veterinary license agreement with closely held Trophogen of Rockville, MD that gives Bioniche commercial access to a patented, proprietary superagonist hormone technology platform developed by Trophogen and originally licensed from the National Institutes of Health. The technology will initially be developed into a next-generation follicle stimulating [...]

Riding the Next Wave

No, we’re not talking about the north coast of Maui but rather a new research platform from long-time biotech analyst David Martin of Dundee Securities. “If I’m going to recommend that investors own a basket of biotech stocks, it makes sense that I ought to initiate on a basket of stocks rather than make one-off [...]